Skip to main content

Together we are beating cancer

Donate now
  • Health & Medicine

Lung cancer: final phase of ‘encouraging’ thalidomide trial to launch

The Cancer Research UK logo
by Cancer Research UK | News

28 January 2003

0 comments 0 comments

A large-scale randomised clinical trial to investigate the effectiveness of thalidomide as a treatment for lung cancer is set to begin at the end of February 2003.

The Cancer Research UK-funded trial is the third stage in tests on a thalidomide and chemotherapy treatment for Small Cell Lung Cancer – a notoriously difficult type of lung cancer to treat. Around 400 patients will be recruited to take part.

The decision to go ahead with the final trial follows encouraging preliminary results from a smaller trial started in 2000. Forty per cent of the patients on that trial survived for more than a year. This compares well with the usual rate of 21 per cent for one-year survival.

Thalidomide hit the headlines in the 1960s when it was discovered that it caused birth defects by limiting blood flow to developing limbs.

The current trial, led by Dr Siow Ming Lee, who is based at University College London and Middlesex Hospital, will investigate this property of blood flow limitation to see if it can offer hope of new treatments to lung cancer patients.

Dr Lee believes that thalidomide not only stops new tumour blood vessel growth – preventing cancer spread and tumour growth – but that it also has immune stimulating properties against the cancer cells and stabilises existing blood vessels.

The stabilised vessels allow a smooth flow of blood to the core of the tumour – delivering cancer killing chemotherapy drugs and the oxygen needed for the chemotherapy to work effectively.

The blood flow to tumours normally pulses rather than flows – reducing the effectiveness of the chemotherapy treatment.

Dr Lee says: “Results from earlier tests have been encouraging. The outlook with existing treatments for small cell lung cancer remains poor – this is why we must look for innovative methods of treating the disease.”

In the earlier tests patients were given chemotherapy with thalidomide. This large scale test will investigate the advantages of giving thalidomide with chemotherapy compared to chemotherapy alone.

“We need to investigate whether the combined treatment is more effective than standard chemotherapy alone. Even minor improvements at this stage could result in many lives being saved in the future,” says Dr Lee.

Thalidomide also has a range of potential positive side-effects. A common symptom of the disease is rapid weight loss and fatigue. The drug stimulates weight gain, enhances appetite and improves sleeping patterns. All of these can significantly improve the quality of life for cancer patients.

While patients who undergo traditional chemotherapy treatment have a high remission rate, the cure rate is very low. In 1996 this form of lung cancer was responsible for around 9,000 deaths in the UK.

The trial will be run from a number of centres across the UK – including UCL Hospitals, The Whittington Hospital, Barts and The London.

Sir Paul Nurse, Chief Executive of Cancer Research UK, says: “The use of thalidomide offers us scope for optimism, any improvement we can get on the existing survival figures would be very welcome news.”